1st ER morphine designed to deter abuse when crushed
from Monthly Prescribing Reference
The Food and Drug Administration has approved new labeling for Embeda (morphine sulfate and naltrexone HCl; Pfizer) extended-release (ER) capsules to include abuse-deterrence studies. Embeda is indicated for the treatment of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. The new abuse-deterrent labeling includes data indicating that the drug has properties that are expected to reduce oral and intranasal abuse when it is crushed, though abuse by these routes is still possible.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063